Abstract 2904
Background
Up to three-quarters of colorectal cancer (CRC), survivors may experience one or more physical, psychological or social issues after treatment. Individuals with a cancer diagnosis report appropriate support and information from healthcare professionals during treatment. However, many are unprepared for the chronic effects of cancer and its treatment and lack the resources to devise self-management skills. This study aims to design and develop an evidence-based Cancer Survivorship Information Resource (CSIR) to support the education of people with CRC about potential survivorship issues.
Methods
The CSIR is being developed with key stakeholders via a three-phase participatory action research (PAR) approach. In Phase 1, chronic effects of CRC were explored in a mixed methods study (n = 304). In Phase 2, a 3-round modified Delphi was undertaken with key stakeholders, including CRC survivors, healthcare professionals and advocates to gain consensus on topics to be included in the CSIR (n = 36). Phase 3 will focus on the design, development and evaluation of the CSIR.
Results
In phase 1, CRC survivors reported symptoms including sexual dysfunction (66%), fatigue (64%), bowel dysfunction (57%) and fear of recurrence (60%). Seventeen survivorship information topics were identified in Phase 1; six further topics were proposed by Phase 2 participants. Seventeen items achieved agreement (≥80%) for inclusion in the CSIR, including fatigue, bowel function, sexual function, coping, and returning to work.
Conclusions
Stakeholder consensus and engagement has the potential to effect sustainable change and innovation in practice. Phase 2 participants will be engaged in Phase 3 to develop and evaluate the content of the CSIR. PAR methodology facilitates the development of interventions which are person-centred and appropriate to the stage of treatment. Once developed, the CSIR will form part of a larger complex intervention, which aims to address the unmet information and supportive care needs of cancer survivors; supporting them to develop self-management skills to cope with the chronic effects of CRC and its treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Trinity College Dublin.
Funding
The Health Research Board Research Training Fellowship for Healthcare Professionals (Grant#: HPF.2014.715).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1242 - Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data.
Presenter: Roger Cohen
Session: Poster Display session 3
Resources:
Abstract
4703 - Updated results of a phase II study evaluating accelerator-based boron neutron capture therapy (AB-BNCT) with borofalan(10B) (SPM-011) in recurrent squamous cell carcinoma (R-SCC-HN) and recurrent and locally advanced non-SCC (R/LA-nSCC-HN) of the head and neck
Presenter: Katsumi Hirose
Session: Poster Display session 3
Resources:
Abstract
3638 - Phase 3 KEYNOTE-048 Study of First-Line (1L) Pembrolizumab (P) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Asia vs Non-Asia Subgroup (subgrp) Analysis
Presenter: Makoto Tahara
Session: Poster Display session 3
Resources:
Abstract
2954 - Integrated data review evaluating safety, pharmacokinetics (PK) and immunogenicity of RM-1929 photoimmunotherapy (PIT) in subjects with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
3629 - First line versus second line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
Presenter: Caroline Even
Session: Poster Display session 3
Resources:
Abstract
767 - Sensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy
Presenter: Theodoros Rampias
Session: Poster Display session 3
Resources:
Abstract
4985 - A Single-Arm, Open-Label, Multicenter, Phase IIIb Clinical Trial with Nivolumab in Subjects with Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck.
Presenter: Paolo Bossi
Session: Poster Display session 3
Resources:
Abstract
1564 - Long-term Results of Phase 2 Trial of Reduced Modified Clinical Target Volume in Low-risk Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiotherapy
Presenter: Jingjing Miao
Session: Poster Display session 3
Resources:
Abstract
3356 - To compare two oral mucosa contouring methods in predicting acute oral mucocitis in nasopharyngeal carcinoma treated with helical tomotherapy
Presenter: Yuan-Yuan Chen
Session: Poster Display session 3
Resources:
Abstract
1984 - Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC)
Presenter: Gizem Kaval
Session: Poster Display session 3
Resources:
Abstract